Ablation for hepatocellular carcinoma: beyond the standard indications.
Ablation
Clinical indications
Hepatocellular carcinoma
Precision medicine
Tumour stage
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
12 Mar 2020
12 Mar 2020
Historique:
received:
12
12
2019
accepted:
20
02
2020
entrez:
14
3
2020
pubmed:
14
3
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC), the most common primary liver neoplasia, represents the fifth most common malignant disease in men. Percutaneous ablation treatment is recommended among the treatments suggested for HCC patients in the very early/early stage. In the last decade, very important results in terms of survival benefits have been obtained with local ablative therapies, also outside the standard indications, thanks to many technical innovations. In particular, important results of ablation as a safe and effective technique have been obtained in the treatment of intermediate- or advanced-stage patients with HCC, and in the treatment of unfavourable tumour locations. Moreover, awareness is growing regarding the necessity of overcoming the rigidity of traditional guidelines in the treatment of HCC due to the complexity of patients with HCC, focusing on Precision Medicine. In this context, it is important to know the standard and non-standard indications of ablation in the treatment of HCC in order to offer the best therapeutic option tailored for each patient. The aim of this study was to analyse the possible clinical applications of ablative therapies for HCC patients, beyond the traditional indications recommended in the most widespread clinical practice guidelines for the management of HCC.
Identifiants
pubmed: 32166482
doi: 10.1007/s12032-020-01348-y
pii: 10.1007/s12032-020-01348-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23Références
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
Liver Int. 2017 Mar;37(3):423-433
pubmed: 27566596
World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):477-489
pubmed: 27867681
J Clin Oncol. 2018 Jul 1;36(19):1913-1921
pubmed: 29498924
Curr Med Res Opin. 2015 Aug;31(8):1553-60
pubmed: 26067770
Hepat Oncol. 2016 Apr;3(2):119-136
pubmed: 30191033
Eur J Radiol. 2012 Oct;81(10):2717-25
pubmed: 22245655
World J Gastroenterol. 2019 Aug 21;25(31):4360-4382
pubmed: 31496618
Radiology. 2000 Mar;214(3):761-8
pubmed: 10715043
World J Gastroenterol. 2014 Apr 21;20(15):4115-27
pubmed: 24764650
Dig Liver Dis. 2019 Aug;51(8):1067-1073
pubmed: 31208929
J Vasc Interv Radiol. 2004 Sep;15(9):901-5
pubmed: 15361556
Eur J Radiol. 2014 Oct;83(10):1793-8
pubmed: 25052871
Eur J Gastroenterol Hepatol. 2019 Mar;31(3):283-288
pubmed: 30234643
Cancer Treat Rev. 2006 Dec;32(8):594-606
pubmed: 17045407
Korean J Radiol. 2013 Mar-Apr;14(2):248-58
pubmed: 23483753
Liver Cancer. 2014 Oct;3(3-4):458-68
pubmed: 26280007
Eur J Gastroenterol Hepatol. 2013 Feb;25(2):187-94
pubmed: 23134976
Hepatol Res. 2015 Jan;45(2):
pubmed: 25625806
Lancet Oncol. 2017 Dec;18(12):1624-1636
pubmed: 29107679
World J Gastroenterol. 2017 Aug 7;23(29):5282-5294
pubmed: 28839428
World J Hepatol. 2015 May 18;7(8):1054-63
pubmed: 26052394
Liver Int. 2016 Jan;36 Suppl 1:124-9
pubmed: 26725909
Digestion. 2012;85(1):18-26
pubmed: 22156507
Anticancer Res. 2016 Nov;36(11):6179-6183
pubmed: 27793949
J Cancer Res Clin Oncol. 2009 Jun;135(6):783-9
pubmed: 19034515
Radiol Med. 2013 Jun;118(4):555-69
pubmed: 23358819
Ann Surg Oncol. 2011 Jul;18(7):1964-71
pubmed: 21267791
BMC Cancer. 2014 Nov 19;14:849
pubmed: 25409554
J Gastroenterol Hepatol. 2016 Jan;31(1):69-80
pubmed: 26312574
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
J Hepatol. 2018 Apr;68(4):783-797
pubmed: 29031662
Cancer. 2010 Dec 1;116(23):5452-60
pubmed: 20672352
Liver Cancer. 2016 Feb;5(1):8-20
pubmed: 26989656
Radiology. 2014 Aug;272(2):598-604
pubmed: 24689883
Eur J Radiol. 2016 Apr;85(4):739-43
pubmed: 26971417
Eur Surg. 2018;50(3):117-124
pubmed: 29875800
Hepatol Res. 2016 Jan;46(1):58-71
pubmed: 26265000
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
pubmed: 15761078
J Vasc Interv Radiol. 2009 Jan;20(1):118-24
pubmed: 19019701
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Clin Res Hepatol Gastroenterol. 2016 Jun;40(3):309-314
pubmed: 26428660
Br J Radiol. 2011 Aug;84(1004):691-7
pubmed: 21750136
Liver Int. 2010 May;30(5):741-9
pubmed: 20331507
World J Gastroenterol. 2016 Feb 14;22(6):1935-42
pubmed: 26877601
Dig Dis. 2014;32(6):696-704
pubmed: 25376286
Eur Radiol. 2018 Feb;28(2):506-513
pubmed: 28894901
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
J Gastroenterol Hepatol. 2017 Mar;32(3):695-700
pubmed: 27597181
Hepatol Res. 2016 Apr;46(4):312-9
pubmed: 26224167
HPB (Oxford). 2014 Aug;16(8):758-67
pubmed: 24467780
Hepatobiliary Pancreat Dis Int. 2016 Aug;15(4):378-85
pubmed: 27498577
Med Oncol. 2011 Dec;28(4):1038-43
pubmed: 20632218
Radiology. 2016 Jul;280(1):300-12
pubmed: 26824711
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Eur Radiol. 2018 Sep;28(9):3611-3620
pubmed: 29633000
J Natl Compr Canc Netw. 2009 Apr;7(4):350-91
pubmed: 19406039
World J Hepatol. 2015 May 28;7(9):1184-91
pubmed: 26019734
Oncology. 2015;89 Suppl 2:19-26
pubmed: 26584032
Hepat Mon. 2012 Oct;12(10 HCC):e5945
pubmed: 23162600
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Adv Exp Med Biol. 2018;1032:55-69
pubmed: 30362090
Hepatology. 2018 May;67(5):1784-1796
pubmed: 29159910
Curr Probl Surg. 2010 Jan;47(1):10-67
pubmed: 19963083
Clin Radiol. 2014 Jun;69(6):e253-63
pubmed: 24581962
World J Gastroenterol. 2013 Jun 28;19(24):3872-82
pubmed: 23840128
Semin Liver Dis. 2012 Nov;32(4):348-59
pubmed: 23397536